RxDoctor Payments Data

Alyssa Branson

Nurse Practitioner · Belleville, ILNPI 1245953470

Payments from drug & device makers

$4,109in general payments, 2019–2025

Across 245 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$922
  • Pfizer$420
  • AbbVie$384
  • Novartis$284
  • Amgen$267
  • Lilly USA, LLC$232
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,109100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,109 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$21,675
Medicare patients
112
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$14,458
MounjaroTirzepatide13$14,374
XareltoRivaroxaban19$12,395
FarxigaDapagliflozin Propanediol16$11,780
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$8,589
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,741
Albuterol Sulfate HfaAlbuterol Sulfate20$736
Omega-3 Acid Ethyl Esters12$530
Fluticasone Propionate21$525
Cyclobenzaprine Hcl42$513
Atorvastatin Calcium36$453
Levothyroxine Sodium42$401
Duloxetine Hcl11$372
Gabapentin23$351
Omeprazole22$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$224$14,45813 claims
Lilly USA, LLCMounjaro$232$14,37413 claims
Johnson & JohnsonXarelto$220$12,39519 claims
AstraZenecaFarxiga$922$11,78016 claims
GSKTrelegy Ellipta$17$7,74112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Belleville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →